Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies

Current Opinion in Investigational Drugs

Volumn 10, Issue 6, 2009, Pages 579-587

  Khubchandani, Sapna ^a   Czuczman, Myron S ^a   Hernandez Ilizaliturri, Francisco J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACETUZUMAB; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; B CELL LYMPHOMA; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONJUNCTIVITIS; CYTOTOXICITY; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; FATIGUE; FEVER; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; LARGE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA, B-CELL; MACACA FASCICULARIS; MICE; MULTIPLE MYELOMA; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650657178     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 394017 Seattle Genetics mAbs for cancer: Lead agentss Seattle Genetics Inc COMPANY WORLD WIDE WEB SITE 2000 December 18
2. 427644 TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC BLOOD 2001 98 3 795-804
3. 435206 Seattle Genetics announces that its anti-CD40 monoclonal antibody enters clinical development at Genentech. Seattle Genetics Inc PRESS RELEASE 2002 January 08
4. 445525 CD40 and CD154 in cell-mediated immunity. Grewal IS, Flavell RA ANNu REv IMMuNOL 1998 16 111-135
5. 528888 Seattle Genetics initiates SGN-40 phase I clinical trial in multiple myeloma. Seattle Genetics Inc PRESS RELEASE 2004 March 25
6. 555947 Seattle Genetics granted Orphan Drug status for SGN-40 in multiple myeloma. Seattle Genetics Inc PRESS RELEASE 2004 August 24
7. 572658 Enhanced cytotoxicity of monoclonal antibody SGN-40 and immunomodulatory drug IMiD3 against human multiple myeloma. Tai YT, Catley L, Li XF, Hamasaki M, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Streon SP, Munshi NC et al BLOOD 2004 104 11 Abs 1498
8. 573731 A phase I, multi-dose, dose escalation study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma. Hussein MA, Niesvizky R, Munshi N, Berenson JC, Anderson KC, Ryan K, Baumgartner K, Miller DM, McDonald M BLOOD 2004 104 11 Abs 2413
9. 578924 Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P et al CANCER RES 2005 64 8 2846-2852
10. 597662 Synergistic cytotoxicity of immunomodulatory drug IMiD3 and monoclonal antibody SGN-40 against human multiple myeloma. Tai YT, Catley L, Li XF, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Munshi NC, Anderson KC PROC AM ASSOC CANCER RES 2005 46 Abs 5011
11. 601460 A humanized anti-CD40 monoclonal antibody (SGN-40) demonstrates antitumor activity in non-Hodgkin's lymphoma: Initiation of a phase I clinical trial. Drachman JG, Law C, Furman RR, Baumgartner K, Kunkel LA, Ryan K, Miller D, McDonald M, Grewal IS PROC AM SOC CLIN ONCOL 2005 24 Abs 6572
12. 603205 Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma. Hussein MA, Berenson JR, Niesvizky R, Munshi NC, Anderson KC, Ryan KL, Baumgartner KT, Miller DM, Drachman JR, McDonald M PROC AM SOC CLIN ONCOL 2005 24 Abs 6581
13. 637938 Seattle Genetics expands SGN-40 clinical program into chronic lymphocytic leukemia. Seattle Genetics Inc PRESS RELEASE 2005 November 30
14. 638720 The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's disease cells through multiple mechanisms. Law CL, McEarchern JA, Cerveny JG, Smith LM, Nesterova A, Gordon KA, Grewal IS, Wahl AF BLOOD 2005 106 11 Abs 1476
15. 638743 A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. Advani RH, Furman RR, Rosenblatt JD, Younes A, Forero-Torres A, Harrop KL, Baumgartner KT, McDonald M, Drachman JG BLOOD 2005 106 11 Abs 1504
16. 639919 Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Tai YT, Catley L, Li XF, Coffey R, Breitkreutz I, Bae J, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P et al BLOOD 2005 65 24 11712-11720
17. 641128 A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Hussein MA, Berenson JR, Niesvizky R, Munshi NC, Harrop KL, McDonald M, Drachman JG BLOOD 2005 106 11 Abs 2572
18. 641565 Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation. Gowda AC, Zhao XB, Cheney C, Mehter N, Lozanski G, Lin TS, Guster S, Drachman JG, Muthusamy N, Byrd JC BLOOD 2005 106 11 Abs 2966
19. 671212 A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Harrop K, DrachmanJG, Advani R PROC AM SOC CLIN ONCOL 2006 25 Abs 7534
20. 750224 The humanized anti-CD40 antibody, SGN-40, promotes apoptosis signaling and is effective in combination with standard therapies in lymphoma xenograft models. Lewis TS, Sutherland MSK, Jonas M, Cerveny CG, McCormick R, Wahl AF, Drachman JG, Grewal IS, Law C-L BLOOD 2006 108 11 Abs 2499
21. 750206 SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Shankles B, Harrop K, Drachman JG BLOOD 2006 108 11 Abs 695
22. 750857 Results of a phase I trial of SGN-40 (Anti-huCD40 mAb) in patients with relapsed multiple myeloma. Hussein MA, Berenson JR, Niesvizky R, Munshi NC, Matous J, Harrop K, Drachman JG BLOOD 2006 108 11 Abs 3576
23. 752974 Seattle Genetics starts phase II B-cell lymphoma trial of SGN-40. Seattle Genetics Inc PRESS RELEASE 2006 December 20
24. 755878 Genentech licenses Seattle's SGN-40 for cancer. Genentech Inc PRESS RELEASE 2007 January 08
25. 800388 Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Ofazoglu E, Grewal IS BR J PhARMACOL 2006 148 8 1116-1123
26. 800396 Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF et al CANCER RES 2005 65 18 8331-8338
27. 843770 The humanized anti-CD40 monoclonal antibody, SGN-40, signals apoptosis in non-Hodgkin's lymphoma by dual mechanisms. McCormick RS, Lewis TS, Miyamoto J, Sutherland MSK, Drachman JG, Grewal IS, Law CL AACR-NCI-EORTC INT CONgRESS 2007 19th October 24 Abs B63
28. 859219 Seattle Genetics initiates SGN-40 phase IIb clinical trial in combination with Rituxan and chemotherapy for diffuse large B-cell non-Hodgkin's lymphoma. Seattle Genetics Inc PRESS RELEASE 2007 December 10
29. 859793 The humanized anti-CD40 monoclonal antibody, SGN-40, potentiates chemotherapy regimens in NHL xenograft models via pro-apoptotic signaling. Seattle Genetics Inc AM SOC hEMATOL ANN MEET EXPOSITION 2007 49th December 09 Abs 2342
30. 865693 Seattle Genetics receives dacetuzumab-related milestone payment from Genentech. Seattle Genetics Inc PRESS RELEASE 2008 January 07
31. 913813 Seattle Genetics reports fnal SGN-40 phase I non-Hodgkin lymphoma data at international conference on malignant lymphoma. Seattle Genetics Inc PRESS RELEASE 2008 June 05
32. 921958 SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: Final results of a phase I dose-escalation study. Anonymous ANNALS OF ONCOLOgY 2008 19 Suppl 4 115
33. 944587 The role of complement in the mechanism of action of rituximab for B-cell lymphoma: Implications for therapy. Zhou X, Hu W, Qin X ONCOLOgIST 2008 13 9 954-966
34. 966939 A phase 2 clinical trial of SGN-40 monotherapy in relapsed diffuse large B-cell lymphoma. Advani R, De Vos S, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Dornan D, Whiting N et al AM SOC hEMATOL ANN MEET EXPOSITION 2008 50th December 6 Abs 1000
35. 967205 Preclinical analysis of the combined activity of SGN-40, anti-CD40 monoclonal antibody, with rituximab in non-Hodgkin lymphoma. Lewis TS, McCormick RS, McEarchern JA, Kissler K, Stone IJ, Gerber HP, Drachman JG, Grewal I, Law CL AM SOC hEMATOL ANN MEET EXPOSITION 2008 50th December 6 Abs 1583
36. 967230 Identifcation of a diagnostic gene signature for SGN-40, anti-CD40 monoclonal antibody, in pre-clinical NHL models and the role of FAS in SGN-40 mediated apoptosis. Shi X, Burington B, Januario T, Lau JT, Yu SF, Ebens A, Dornan D AM SOC hEMATOL ANN MEET EXPOSITION 2008 50th December 6 Abs 1593
37. 977732 Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Ofazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP BR J CANCER 2009 100 1 113-117
38. 983719 Roche: Pharmaceutical pipeline. Roche Holding AG COMPANY WORLD WIDE WEB SITE 2009 January 23
39. 988573 The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N et al BR J hAEMATOL 2009 144 6 848-855
40. 989046 Anti-CD 40 monoclonal antibody. Geldart T, Illidge T LEukEMIA AND LYMPhOMA 2005 46 8 1105-1113
41. 989048 A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P CANCER IMMuNOL IMMuNOThER 1985 20 1 23-28
42. 989052 Inhibition of human B-cell lymphoma growth by CD40 stimulation. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ BLOOD 1994 83 10 2787-2794
43. 989054 Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC CANCER RES 1999 59 6 1287-1294
44. 989056 Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infltrating lymphoid cells.
45. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS AM J PAThOL 1995 147 4 1152-1160
46. 989059 CD40 and epithelial cells: Across the great divide. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW IMMuNOL TODAY 1998 19 11 502-506
47. 989067 CD40 is functionally expressed on human breast carcinomas: Variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP BREAST CANCER RES TREAT 1998 50 1 27-36
48. 989073 A novel function of CD40: Induction of cell death in transformed cells. Hess S, Engelmann H J EXP MED 1996 183 1 159-167
49. 989075 CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC et al ONCOgENE 1996 13 10 2243-2254
50. 989077 CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, Young LS MOL CELL BIOL 2000 20 15 5503-5515
51. 989080 Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: Induction of bax. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, Boyd A, Taub DD, Durum SK, Siegall CB, Longo DL et al BLOOD 2002 100 1 217-223
52. 989081 Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ BLOOD 1999 93 9 2999-3007
53. 989082 The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK J NATL CANCER INST 2002 94 18 1381-1395
54. 989089 Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ CLIN CANCER RES 2001 7 3 691-703
55. 989096 Recombinant CD40 ligand therapy has signifcant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Ghamande S, Hylander BL, Ofazoglu E, Lele S, Fanslow W, Repasky EA CANCER RES 2001 61 20 7556-7562
56. 989099 Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM Jr CLIN CANCER RES 1999 5 8 2261-2270
57. 989103 Tumour dormancy and cell signalling-III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hsueh R, Vitetta ES, Scheuermann RH, Uhr JW ThER IMMuNOL 1995 2 3 125-136
58. 989104 Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Nuckel H, Frey UH, Roth A, Duhrsen U, Siffert W EuR J PhARMACOL 2005 514 2-3 217-224
59. 989204 The role of the CD40 pathway in the pathogenesis and treatment of cancer. Eliopoulos AG, Young LS CuRR OPIN PhARMACOL 2004 4 4 360-367
60. 989206 Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG J BIOL ChEM 2004 279 2 1010-1019
61. 989222 Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G et al CLIN CANCER RES 2003 9 10 Pt 2 3982S-3990S
62. 997499 Dacetuzumab (SGN-40), a humanized anti-CD40 monoclonal antibody, has chemosensitization activity and improves gemcitabine effcacy in NHL xenograft models. Lewis TS, McCormick RS, Stone IJ, Gerber HP, Mbow B, Whiting NC, Drachman JG, Grewal IS, Law CL AM ASSOC CANCER RES ANN MEET 2009 100th April 21 Abs 3243
63. 998975 Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'. Planken EV, Dijkstra NH, Willemze R, Kluin-Nelemans JC LEukEMIA 1996 10 3 488-493
64. 998976 Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest. Marshall-Clarke S, Owen G, Tasker L CELL IMMuNOL 1994 156 42 272-285
65. 1006457 A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma. Burington B, Advani R, Shi X, Yue P, Lau JT, Yu SF, Januario T, De Vos S, Ansell S, Forero-Torres A, Ebens A et al AM ASSOC CANCER RES ANN MEET 2009 100 April 20